Solution Architect - Process Intelligence
About the job
- Bachelor’s degree in Computer Science, Information Systems, Engineering, or related field (Master’s preferred).
- 8+ years of experience in data architecture, solution architecture, or analytics platform architecture roles.
- Hands-on experience with the Celonis platform, including data integration, PQL (Process Query Language), object-centric data modeling, and Studio asset development.
- Strong expertise in SQL, relational database design, and ERP data schemas (Oracle JDE, SAP, or equivalent).
- Experience designing and operating ETL/ELT data pipelines at enterprise scale.
- Demonstrated ability to define data governance frameworks, quality standards, and architectural documentation.
- Experience with platform administration including SSO, user provisioning, and role-based access control.
- Ability to lead technical delivery in a global, matrixed organization and serve as a technical mentor for colleagues with less experience.
- Strong communication skills with the ability to explain complex technical concepts to both technical and non-technical audiences, including executive stakeholders.
- High level of independence, sound judgment, and ability to operate effectively in ambiguous, greenfield environments.
- Define and maintain the enterprise event log architecture, object-centric data models (OCDM), Perspectives, and Knowledge Model that enable process mining, conformance analysis, variant detection, and KPI measurement across enterprise processes. Own the technical design decisions that determine how business objects, events, and relationships are modeled within the platform (25%).
- Own the end-to-end data integration strategy from source ERP systems (Oracle JDE) into the Celonis platform, including connector configuration, extraction method selection (JDBC, REST, batch vs. real-time), transformation scripts (PQL), data integration scheduling, and pipeline orchestration. Ensure stable, performant, and governed data flows that meet SLA requirements (20%).
- Serve as the technical owner of the Celonis Process Management (CPM) environment, including Process Designer, Navigator, and the enterprise process repository. Manage platform administration including SSO configuration, user roles and permissions, Home Site configuration, and release cycle governance. Ensure the CPM environment is operationally ready for enterprise-scale BPMN modeling and process catalog consumption (15%).
- Serve as the primary technical counterpart to the Celonis SI team during the implementation engagement (May–September 2026). Lead knowledge transfer activities across all SOW phases(Connect, Data Ready, Analyze, Execute, Handover) and ensure internal capability is built to sustain, operate, and evolve the platform independently post-engagement. Shadow SI consultants during OCDM configuration, Studio asset development, and Action Flow design (15%).
- Establish and govern the data quality framework — including validation rules, reconciliation procedures, data scorecards, and root‑cause resolution workflows — to ensure mining outputs are accurate, consistent, and audit-ready. Define acceptance criteria for event logs and analytical assets before publication to business stakeholders (10%).
- Provide technical leadership and mentorship to the Process Intelligence Data Engineer (P3), Senior Analyst, Process Excellence (P3), and broader Pune BPM execution team. Define technical standards, conduct architecture reviews, establish reusable templates and patterns, and ensure alignment with Edwards enterprise IT governance and security requirements (10%).
- Evaluate and recommend adoption paths for emerging Celonis capabilities (e.g., Process Sphere, Action Flows, Agent C, AI-driven insights) aligned to Edwards’ process intelligence roadmap. Configure and validate execution solutions including Action Flows and Business Apps for prioritized value opportunities (5%).
- Celonis certification(s) such as Celonis Data Engineer, Celonis Analyst, or Celonis Solution Architect.
- Experience with Celonis Process Management (CPM/Symbio), including Process Designer and Navigator.
- Experience implementing Celonis from greenfield (not just operating an existing deployment).
- Experience with cloud data platforms (Azure, AWS) and modern data stack tooling.
- Python or other scripting language proficiency for data automation, validation, and pipeline orchestration.
- Experience operating in regulated industries (e.g., medical device, pharmaceuticals) requiring data integrity, audit readiness, and SOX compliance.
- Familiarity with BPMN 2.0 process modeling standards and process excellence methodologies (Lean, Six Sigma).
- Experience with Action Flows, Business Apps, or similar execution/automation solutions within process mining platforms.
About the company
Edwards Lifesciences focuses on cardiovascular medical technologies, especially transcatheter heart valves. Its products enable repairing or replacing diseased heart valves through minimally invasive procedures rather than open-heart surgery. The company builds on a long history that began with the Starr-Edwards valve and now centers on valve therapies and related diagnostics to treat heart disease. It differentiates itself by specializing in valve technologies and transcatheter approaches, backed by a track record of clinical leadership and global reach. The goal is to improve patient outcomes by providing safer, less invasive valve treatment options for people around the world.
Company Size
10,001+
Company Stage
IPO
Headquarters
Irvine, California
Founded
1958
Get referred to Edwards Lifesciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- CMS finalized expanded TAVR coverage September 10, 2026, enlarging addressable Medicare volume.
- Q2 2026 sales rose 13.6% to $1.74 billion; management raised full-year guidance.
- AUTUS approval and ECLIPTIS launch broaden growth beyond mature TAVR programs.
What critics are saying
- FTC settled July 2026 JC Medical charges for $10 million and compliance oversight.
- January 2026 injunction blocked JenaValve buyout, crippling Edwards' aortic-regurgitation acquisition strategy.
- AtriaCure, Medtronic, and Boston Scientific attack Edwards' adjacencies; failure here destroys diversification.
What makes Edwards Lifesciences unique
- Edwards owns SAPIEN TAVR leadership and the 2025 asymptomatic-label exclusivity.
- AUTUS, approved October 1, 2026, creates a pediatric pulmonary-valve franchise.
- ECLIPTIS, cleared July 2026, extends Edwards into surgical stroke-prevention during cardiac surgery.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Growth & Insights and Company News
6 month growth
1%1 year growth
10%2 year growth
10%Edwards Lifesciences (EW) receives a Buy from RBC Capital. Oct. 2, 2026, 09:46 PM RBC Capital analyst Kendall Au maintained a Buy rating on Edwards Lifesciences on October 1 and set a price target of $110.00. The company's shares closed yesterday at $85.19. Au covers the Healthcare sector, focusing on stocks such as Becton Dickinson, GE Healthcare Technologies Inc, and Boston Scientific. According to TipRanks, Au has an average return of -3.6% and a 22.22% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Edwards Lifesciences with a $103.40 average price target, representing a 21.38% upside. In a report released on September 28, Leerink Partners also reiterated a Buy rating on the stock with a $101.00 price target. Based on Edwards Lifesciences' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.74 billion and a net profit of $241.9 million. In comparison, last year the company earned a revenue of $1.53 billion and had a net profit of $329.8 million Based on the recent corporate insider activity of 110 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year. Most recently, in August 2026, Annette Bruls, the CVP, EMEACLA of EW sold 2,644.00 shares for a total of $237,907.12. Read More on EW:
Edwards Lifesciences has received FDA approval for the AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed specifically for paediatric patients with congenital heart disease. The valve can be expanded as a child grows through a minimally invasive transcatheter procedure, potentially reducing the need for repeat open-heart surgeries. The approval was based on a pivotal study that met its primary safety and effectiveness endpoints. All patients were free from device-related complications through 30 days, with no valve reinterventions through six months. Patients who completed one-year follow-up showed consistent outcomes with favourable valve performance. The AUTUS valve previously received FDA Breakthrough Device designation for addressing an important unmet need in paediatric cardiac care.
Edwards Lifesciences, an Irvine, California-based cardiovascular products company, has underperformed the Dow Jones Industrial Average in recent months. The stock is down 6.6% from its 52-week high of $96.29 reached on 7 July. Over the past three months, Edwards Lifesciences shares grew 2.8%, lagging the Dow's 3.5% gain. The 52-week performance shows similar underperformance, with the stock up 11.4% compared to the Dow's 17.1% increase. Despite this, the company reported strong Q2 results on 23 July, with net sales rising 13.6% year-over-year to $1.7 billion. Adjusted earnings per share of $0.78 beat Wall Street estimates. The company raised its 2026 sales growth guidance to 10-11% from 9-11% previously. Analysts maintain a "strong buy" consensus rating, with a mean price target suggesting 13.5% upside potential.
Edwards Lifesciences to present at the Deutsche Bank Healthcare Summit. Key Takeaway: Edwards Lifesciences Corporation will present at the Deutsche Bank Healthcare Summit on September 16, 2026. CEO Bernard Zovighian and CFO Doretta Mistras will represent the company. A live webcast of the presentation will be available on their investor relations website. Market sentiment analysis. Positive factors. * Edwards Lifesciences is actively engaging with investors. * Participation in a prominent healthcare summit highlights company visibility. * CEO and CFO are presenting, indicating strong leadership presence. IRVINE, Calif.-(BUSINESS WIRE)-Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl Frequently asked questions. When will Edwards Lifesciences present at the summit? Edwards Lifesciences will present on September 16, 2026. Who will represent Edwards Lifesciences at the summit? CEO Bernard Zovighian and CFO Doretta Mistras will represent the company. Is there a webcast available for the presentation? Yes, a live webcast will be available on their investor relations website.
Antitrust: KKR agrees to record settlement of HSR non-compliance claims. August 31, 2026 Last year, DealLawyers blogged about the DOJ's decision to file a lawsuit against KKR, in which it alleged that the buyout giant engaged in multiple failures to comply with the HSR Act's pre-merger notification requirements. Last week, the parties filed a proposed settlement of that lawsuit with the SDNY. This excerpt from a White & Case memo summarizes the terms of the settlement: On Wednesday, August 26, 2026, the DOJ filed a proposed settlement requiring KKR & Co. Inc. to pay a civil penalty of $250 million, more than 20 times any prior HSR penalty obtained by the DOJ. Associate Attorney General Stanley Woodward indicated that this proposed settlement "sends a powerful message" and shows that the DOJ "is committed to vigorous enforcement of the Act." This settlement comes after the DOJ alleged in January 2025 that the private equity sponsor "repeatedly violated the HSR Act" through "systemic" violations. Key allegations in the DOJ's complaint included: - Failure to submit responsive business documents required under Item 4 of the HSR Form - Altering or removing content and pages in final Item 4 documents before submission to the FTC/DOJ as part of required HSR filings - Failure to make HSR filings before consummating reportable transactions The memo quotes a KKR spokesperson as saying that the organization determined that continuing the litigation would be a distraction to the organization & that KKR was pleased to put the litigation behind it. They also noted that their investors wouldn't feel the bite, because KKR "will be fully reimbursed by outside law firms." Yikes!!! The settlement comes on the heels of last month's settlement of the FTC's actions targeting Edwards Lifesciences & Genesis Medtech's for alleged violations of the HSR Act. At the time, the $12 million fine that the companies agreed to pay was the largest ever for failing to make an HSR filing. I guess records were made to be broken. - John Jenkins